Fluoroquinolones and the risk of tendon injury: a systematic review and meta-analysis
- 441 Downloads
Tendinopathy is a known adverse reaction associated to fluoroquinolones, but a meta-analysis was not yet published. The aim of this study was to conduct a systematic review and a meta-analysis of the scientific evidence evaluating the risk of tendon injury associated with fluoroquinolones.
A literature search was conducted to identify observational studies which reported results on the risk of Achilles tendon rupture (ATR), risk of Achilles tendinitis (AT), or risk of any tendon disorders (ATD). A meta-analysis was performed by pooling odds ratios (ORs) with their 95% confidence intervals (CIs).
Fifteen studies were included in the meta-analysis. Treatment with fluoroquinolones was associated with an increased risk of ATR (OR 2.52 (95% CI 1.81–3.52), p < 0.001, I2 = 76.7%), an increased risk of AT (OR 3.95 (95% CI 3.11–5.01), p < 0.001, I2 = 0%), and increased risk of ATD (OR 1.98 (95% CI 1.62–2.43), p < 0.001, I2 = 84.5%). The initial risk estimates remained statistically significant among patients aged ≥ 60 years old. Risk estimates did not significantly change after depending on the concomitant use of corticosteroids or studies methodological quality assessment. The analysis according to the type of fluoroquinolones was only possible for ATR, which were ofloxacin and norfloxacin were found to increase the risk of this outcome, but not ciprofloxacin and levofloxacin.
The results of this meta-analysis confirm the risk of tendon injuries associated with fluoroquinolones. Older age and concomitant use of corticosteroids seem to be additional risk factors for tendinopathy.
KeywordsFluoroquinolones Tendinopathy Pharmacovigilance Risk assessment Meta-analysis
Carlos Alves conceived and designed the study, performed research, analyzed data, and wrote the paper. Diogo Mendes and Francisco Batel Marques conceived the study and wrote the paper.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 6.US US Food and Drug Administration. FDA News Release. U.S. Food and Drug Administration. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm612995.htm. Accessed 14 May 2019
- 7.US Food and Drug Administration. Postmarket Drug Safety Information for Patients and Providers. http://wayback.archive-it.org/7993/20170112032310/http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126085.htm. Accessed 14 May 2019
- 8.European Medicines Agency. Disabling and potentially permanent side effects lead to uspension or restrictions of quinolone and fluoroquinolone antibiotics. https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-fluoroquinolone-containing-medicinal-products. Accessed 14 May 2019
- 11.van der Vlist AC, Breda SJ, Oei EHG, Verhaar JAN, de Vos RJ (2019) Br J Sports Med. https://doi.org/10.1136/bjsports-2018-099991
- 12.Yu X, Jiang DS, Wang J, Wang R, Chen T, Wang K, Cao S, Wei X (2019) Fluoroquinolone use and the risk of collagen-associated adverse events: a systematic review and meta-analysis. Drug Saf. https://doi.org/10.1007/s40264-019-00828-z
- 20.U.S. National Library of Medicine. Medical Subject Headings 2019. U.S. National Library of Medicine. https://meshb.nlm.nih.gov/search. Accessed 14 May 2019
- 21.ICH MedDRA Maintenance and Support Services Organization (MSSO). International Council for Harmonisation of technical requirements for Pharmaceuticals for Human use (ICH). https://www.meddra.org/. Accessed 14 May 2019
- 22.Elsevier. Embase Indexing and Emtree. https://www.elsevier.com/solutions/embase-biomedical-research. Accessed 14 May 2019
- 23.Wells GA, Shea B, O’Connell D et al (2014). The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 14 May 2019
- 26.B Publication bias (2009) In: Borenstein M, Hedges LV, JPT H, Rothstein HR (eds) Introduction to meta-analysis. Wiley, Chichester, pp 277–291Google Scholar
- 32.Barge-Caballero E, Crespo-Leiro MG, Paniagua-Martín MJ, Muñiz J, Naya C, Bouzas-Mosquera A, Piñón-Esteban P, Marzoa-Rivas R, Pazos-López P, Cursack GC, Cuenca-Castillo JJ, Castro-Beiras A (2008) Quinolone-related Achilles tendinopathy in heart transplant patients: incidence and risk factors. J Heart Lung Transplant 27:46–51CrossRefGoogle Scholar